



AVATAR MEDICAL

- 8 February 2023

AVATAR MEDICAL obtains 2.5M€ as a laureate of the EIC Accelerator

AVATAR MEDICAL was announced as a laureate of the European Innovation Council (EIC) Accelerator programme, securing 2.5M€ in funding.

The EIC Accelerator is Europe's flagship innovation program for identifying, developing and commercializing disruptive technologies. Of the more than one thousand applicants, only 78 companies were recognized, including 9 in France.

AVATAR MEDICAL presented its vision: to put medical imaging at the heart of the surgical practice by making them accessible to surgeons throughout the patient journey. Prior to surgery, we provide a virtual reality experience that allows them to interact with 3D patient representations, or "avatars", to fully communicate their patient's anatomy. We forecast an augmented reality experience that will accompany the surgeon in the operating theater.

An important criterion for this program is the startup's strong growth potential and, in particular, its ability to launch a highly innovative solution in a large market. AVATAR MEDICAL's vision and strong potential to permit less invasive procedures, faster patient recovery times, and increased surgeon productivity within hospitals convinced the jury.

The EIC Accelerator subsidy will enable AVATAR MEDICAL to accelerate the migration of its technology to the cloud. Benefits include a faster and wider access to 3D image visualization within hospitals. In parallel, the company is enhancing its core rendering technology and developing promising clinical applications in conjunction with medical device manufacturers.

"This prestigious award marks the end of a successful year at AVATAR MEDICAL. It coincides with a year that saw the signature of our first major contract with a Medtech company, and the publication of three senology patient cases with the Institut Curie. We also were selected to present our results on visceral aneurysms at the Paris Vascular Insights conference, and at the Veith Symposium in New York with the Marie Lannelongue Hospital," said Xavier Wartelle, CEO of AVATAR MEDICAL. "In addition to this, we were recognized by other important awards in 2022 including: Innov'up Leader PIA laureate, the Grand Prix at Laval Virtual, ranking in the top 100 French dealroom startups and the Innovator's Prize from the Île-de-France region to recognize the work of Jean-Baptiste Masson, CSO and also head of laboratory at Institut Pasteur.



AVATAR MEDICAL

- 8 February 2023

The year 2023 will mark an important year for AVATAR MEDICAL with a forecasted FDA certification, the submission of a CE Mark application, and the launch of our first orthopedic clinical application.

About AVATAR MEDICAL

AVATAR MEDICAL is an innovative spin-off from the Institut Pasteur and Institut Curie. AVATAR MEDICAL was incorporated in Paris, France in July 2020 by an experienced team of French and American co-founders, and also operates in the United States. The company has been recognized by prestigious competitions and programs: Bpifrance i-Lab, Bpifrance i-Nov, the MedFIT award for the most innovative European startup, PR[AI]RIE Institut adhesion, and the NVIDIA Inception program. Full commercial deployment of FDA- and CE-cleared versions of our technology is planned for 2023 and 2024.

For more information:

www.avatarmedical.ai

[LinkedIn](#)

[Twitter](#)

[Vimeo](#)

[Medical Publications](#)

Press Contact:

AVATAR MEDICAL

marie@avatarmedical.ai